Genetics Generation Advancement (GGA) held its annual results presentation on the 7th. Riding on the continued expansion of health-related business opportunities, the company posted NT$660 million in revenue for the previous year, marking a 12% year-on-year increase and achieving a record high for the 11th consecutive year. Net profit after tax grew 91% year-on-year, with earnings per share (EPS) reaching NT$2.05. Notably, revenue from the AI division rose by 35%, as GGA expanded its AI service capabilities. With the advancement of AI-driven drug development and diversified exosome applications, the GGA Group continues to enhance its comprehensive strategy in prevention, diagnosis, and treatment, strengthening its long-term operational advantage.
GGA General Manager Ching-Yuan Kang noted that two key drivers contributed significantly to revenue growth: first, the application of AI in biotechnology innovation, providing value-added services across sectors including biotech, chemical, and semiconductor industries; and second, the development of a proprietary AI model for predicting exosome functionality. Leveraging synergies within the GGA Group, the company has actively engaged in global exosome contract R&D services, AI-based exosome product development, and early cancer detection via exosome-based screening.
As AI rapidly reshapes the global industrial value chain, GGA began investing in smart big data applications in 2010 by establishing a bioinformatics and AI R&D department focused on cross-disciplinary AI innovation. Over the years, it has served Taiwan's leading semiconductor firms, the top three chemical companies, and numerous renowned pharmaceutical enterprises both domestically and internationally. GGA has also built strong partnerships with academia, government agencies, and medical institutions. In 2021, the company expanded this initiative into a Big Data and AI Center, which now supports AI-related services across eight major sectors, serving more than a hundred enterprises and research units.
Kang emphasized that GGA’s "AI-driven Automated Drug Design Platform" can screen tens of millions of AI-generated protein models, focusing on simulation and predictive analysis for new drug development. This platform is expected to be applicable to vaccine development, serology, antiviral, and anti-cancer drug fields.
One notable collaboration is with HanchorBio, a biotech firm developing innovative immuno-oncology therapies. GGA’s AI system has supported HanchorBio’s work on a novel cancer immunotherapy targeting PD-1/PD-L1 checkpoint inhibitors. Compared to traditional drug development methods, the AI-powered approach has shortened the early-stage screening and analytical process by 1.5 years and significantly reduced R&D costs. Additionally, GGA is contributing to rare disease drug development programs for well-known pharmaceutical companies.
Moreover, GGA has extended its AI technology into exosome product development, launching the industry’s most advanced and diverse lineup of AI exosome products. The company is also leading the industry by integrating prenatal amniotic fluid microarray testing with AI-enhanced exosome analysis—offering dual diagnostic applications from a single sample, showcasing its innovation and integration capabilities.
Resource: 訊聯基因去年營收年增12％ AI業績成長35％
